[Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease]

Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(9):39-46.
[Article in Russian]


Based on literature data on the usage of Dopa medications in the treatment of Parkinson's disease (PD), a characteristic of a new complex drug stalevo, which includes levodopa, carbidopa and entacapon (catechol-O-methyltransferase inhibitor), is presented. The authors studied 15 patients with PD, aged 55.6+/-8.7 years, illness duration 7.7+/-3.1 years, who received stalevo during 6 weeks and revealed that stalevo reduced significantly the intensity of main PD symptoms, especially hypotension and rigidity as well as motor fluctuations, and improved general movement and daily activity of patients thus ameliorating their quality of life. The drug is well-tolerable.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Antiparkinson Agents / therapeutic use*
  • Carbidopa / therapeutic use*
  • Catechols / therapeutic use*
  • Drug Combinations
  • Female
  • Humans
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Severity of Illness Index


  • Antiparkinson Agents
  • Catechols
  • Drug Combinations
  • Stalevo
  • Levodopa
  • Carbidopa